Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Grace Therapeutics issued a press release on August 13, 2026, announcing financial results for the three months ended June 30, 2026, including net loss of $15.8 million (vs. $3.4 million prior year), a $13.5 million impairment of IPR&D for GTx-101 and GTx-102, and cash runway through end of 2028. The disclosure is furnished under Item 2.02 "Results of Operations and Financial Condition" with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
PDS Biotechnology issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $9.8 million, operating expenses, interest expense, and cash balance of $5.6 million. The filing includes condensed consolidated statements of operations and selected balance sheet data, which are standard components of a quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-13
Item 5.02
Jill Windrum was appointed as Chief Accounting Officer and Deputy Chief Financial Officer effective August 31, 2026, replacing Brian LaRose as principal accounting officer. This is a material executive appointment to a senior financial leadership role. While the disclosure also includes compensatory arrangements (base salary of $400,000, target bonus of 50%, and sign-on equity awards of $400,000), the principal disclosed action is the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a press release announcing Brookfield Corporation's financial results for the quarter ended June 30, 2026. The exhibit discloses quarterly and last-twelve-months earnings metrics including net income ($703M for Q2 2026), distributable earnings ($1.548B for Q2), and earnings per share ($0.14 diluted), along with detailed operating results by business segment. The 15% increase in earnings per share and record fundraising of $77 billion are material developments affecting investor assessment of the registrant's financial performance and capital deployment capacity.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a press release announcing Brookfield Wealth Solutions' financial results for the quarter and six months ended June 30, 2026. The exhibit discloses key financial metrics including total assets ($205.7 billion), distributable operating earnings ($488 million for Q2, $926 million for six months), net income ($149 million for Q2, net loss of $453 million for six months), and earnings per share ($0.07 for Q2, $0.14 for six months). The release includes consolidated balance sheets, statements of operations, and reconciliations of non-GAAP measures, along with management commentary from the CEO on business performance and strategic initiatives. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-08-13
EX-99.1
Golar LNG has executed an EPC agreement with CIMC Raffles for a fourth FLNG unit with a total budget of approximately US$2.45 billion, representing a material capital commitment and expansion of the company's liquefaction capacity by about 40% to above 12 MTPA. This constitutes a material acquisition or entry into a significant material contract that would affect a reasonable investor's assessment of the company's growth trajectory and capital deployment strategy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Aebi Schmidt issued a press release on August 13, 2026, announcing its financial results for the quarter ended June 30, 2026 (Q2 2026). The disclosure reports key financial metrics including Net Sales of $496m (up 9% YoY), Net Income of $10.5m (up $18m YoY), and Adjusted EBITDA of $42.1m (up 22% YoY), along with full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1, which is the typical form and substance of an earnings_release event under Item 2.02.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-13
EX-99.1
This press release announces positive interim clinical trial data from Eupraxia's Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis, including new symptom response data on odynophagia and dysphagia, with no serious adverse events reported across 130+ patients. While the disclosure reports clinical progress rather than a discrete financial or governance event, the positive efficacy and safety data from an ongoing Phase 1b/2a trial represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development prospects and de-risking trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-13
EX-99.1
This press release announces successful downstream battery testing of lithium carbonate produced from Standard Lithium's South West Arkansas Project pilot plant, demonstrating the suitability of the company's product in real-world LFP battery cell manufacturing. The disclosure validates the SWA Project's process flowsheet and represents a material operational and technological milestone for a near-commercial lithium development company, though it is not a discrete M&A transaction, financial result, or executive change.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a press release disclosing Golar LNG's interim financial results for the second quarter and first half of 2026, including Q2 2026 net income of $38 million, Adjusted EBITDA of $127 million, and Total Golar Cash of $908 million. The document presents detailed financial tables, segment reporting, and balance sheet metrics typical of a quarterly earnings announcement. While the release also discusses operational highlights and capital projects (FLNG orders, contracts), the primary disclosure is the quarterly financial results, making this an earnings_release rather than a periodic_quarterly report.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This is a press release disclosing Osisko Gold's Q2 2026 financial and operating results for the three months ended June 30, 2026. The document reports cash position (~$837.3 million), revenues ($32.7 million), operating income ($8.1 million), and material project developments at the Cariboo Gold Project and Tintic Project. The filing explicitly states "Osisko Gold Group Inc. reports its financial and operating results for the three months ended June 30, 2026" and includes consolidated financial statements and MD&A, making this a standard quarterly earnings release.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing MediWound's second quarter 2026 financial results, including revenue of $3.1 million, operating loss of $9.5 million, and net loss of $7.4 million. The document explicitly states "MediWound Reports Second Quarter 2026 Financial Results" and includes unaudited condensed consolidated financial statements (balance sheet, income statement, and cash flows). This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's financial performance and cash burn trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-13
Item 8.01
Semtech has entered into a definitive agreement to sell its cellular module business to Compal Electronics for $62 million in cash. This is a material disposition of a business unit, approved by both boards, with expected closing in Q4 FY2027. The transaction represents a strategic divestiture to focus resources on higher-conviction product lines (data center and LoRa connectivity), making it a material M&A activity under Item 1.02 or 2.01 standards.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-13
Item 8.01
Delek Logistics announced the pricing of an underwritten public offering of 4,000,000 common units at $50.00 per unit, with an additional 600,000-unit option granted to underwriters. This is a registered public offering of equity securities that will dilute existing unitholders' ownership; the parent company Delek Holdings' stake will decline from 63.0% to approximately 58.0%. The filing explicitly states the offering is made pursuant to an effective shelf registration statement, and the press release was issued in accordance with Rule 134 under the Securities Act.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
X-Energy issued a press release on August 13, 2026 reporting financial results for the quarter ended June 30, 2026, disclosing revenues and grant income of $54.6 million (154% increase YoY), operating expenses, cash flow metrics, and liquidity position. The filing explicitly states "On August 13, 2026, X-Energy, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026" and furnishes the press release as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing JD.com's unaudited financial results for the second quarter and interim six months ended June 30, 2026. The document discloses net revenues of RMB346.4 billion, operating income, net income, diluted EPS, and other key financial metrics for both the quarterly and year-to-date periods, along with segment performance and business highlights. This is a classic earnings release disclosing quarterly and interim financial results.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This is a press release announcing Birkenstock's fiscal third quarter 2026 financial results, including revenue of EUR 720 million (up 13% reported, 15% constant currency), net profit of EUR 110 million, and Adjusted EBITDA of EUR 242 million. The company also raised full-year FY26 guidance for revenue growth to 15% in constant currency and Adjusted EBITDA to at least EUR 710 million. This is a discrete earnings announcement, not a periodic financial report.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-08-13
EX-99.1
The announcement discloses the appointment of Mr. Ying Kang as Assistant Vice President of Finance effective August 13, 2026, with assumption of full oversight of the Finance Department starting August 21, 2026, reporting directly to the CEO. While the exhibit also mentions Dan Xie's departure from the CFO role, the principal disclosed action is Ying Kang's appointment to a senior finance leadership position. This is material as it represents a change in the registrant's financial leadership structure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-13
Item 2.02
SBC Medical Group Holdings issued a press release on August 13, 2026 announcing consolidated financial results for the second quarter ended June 30, 2026, including quarterly revenue of $49 million (up 13% YoY), net income of $11 million (up 335% YoY), and adjusted EBITDA of $20 million (up 32% YoY), along with detailed financial tables and management commentary.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Lithium Americas issued a press release on August 13, 2026 announcing its financial and operational results for Q2 2026 (three months ended June 30, 2026), including unaudited condensed consolidated interim financial statements showing net income of $6.3 million for YTD Q2 2026 versus a loss of $24.8 million in YTD Q2 2025, alongside operational updates on the Thacker Pass lithium project.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Aveanna Healthcare disclosed Q2 2026 financial results showing revenue of $670.5 million (13.7% YoY increase), net income of $40.3 million, and Adjusted EBITDA of $95.4 million, along with raised full-year 2026 guidance for revenue (greater than $2.68 billion) and Adjusted EBITDA (greater than $365 million).
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This is a press release announcing Paysafe's second quarter 2026 financial results, including revenue of $447.4 million (4% growth), net loss of $58.9 million, adjusted net income of $23.1 million, and adjusted EBITDA of $102.8 million. The document includes detailed consolidated financial statements (income statement, balance sheet, cash flows) and updated full-year 2026 guidance. This is a discrete earnings announcement, not a periodic financial report filing, and is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing quarterly financial results for the three months ended June 30, 2026. The filing explicitly states "reported its financial and operational results for the three months and year ended June 30, 2026" with a press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets, statements of income/loss, and detailed financial highlights including revenue ($120k vs $7k), operating loss ($2.9M vs $3.6M), and net loss ($28k vs net income of $1.7M), along with business highlights and management commentary typical of a quarterly earnings disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-13
Item 5.02
Jason O'Byrne was appointed as Chief Financial Officer, principal financial officer, and principal accounting officer of Olema Pharmaceuticals, effective August 11, 2026, approved by the Board on July 28, 2026. The appointment includes compensatory arrangements including a base salary of $545,000, 45% bonus target, $350,000 sign-on bonus, and a 650,000-share option grant. The CEO emphasized O'Byrne's extensive finance and capital markets leadership experience at major biotechnology firms will be essential as the company approaches pivotal clinical data and commercial launch.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-13
Item 8.01
The disclosure announces FDA clearance of an IND application and authorization to proceed with a Phase 3 clinical trial for denifanstat in acne treatment. This is a material regulatory milestone for a biopharmaceutical company that advances a key product candidate toward commercialization, affecting investor assessment of the company's pipeline and development progress. The event is operational/strategic in nature rather than fitting a specific named category.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
SOLV Energy issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $951 million (77% YoY growth), net income of $67 million, and updated full-year 2026 guidance. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
LENSAR issued a press release on August 13, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 revenue of $16.5M (+18% YoY), recurring revenue of $13.7M (+20% YoY), net income of $3.5M (vs. loss of $1.8M in Q2 2025), and Adjusted EBITDA of $3.6M (vs. loss of $0.3M in Q2 2025). The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Parabilis Medicines reported Q2 2026 financial results, including a net loss of $52.5M, R&D expenses of $39.4M, G&A expenses of $11.7M, and cash position of $1.1B. The disclosure also included material business updates on zolucatetide advancement and a $125M Regeneron collaboration.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing Legence Corp.'s Q2 2026 financial results, including record quarterly revenues of $1.26 billion (111% increase YoY), adjusted EBITDA of $154.6 million (114% increase YoY), and raised full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
enCore Energy issued a press release on August 13, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net loss per share of $0.19 versus $0.16 for the same period in 2025, uranium deliveries, operating margins, extraction volumes, and liquidity metrics. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K, with the full text attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release disclosing Falcon's Beyond Global's financial results for the second quarter ended June 30, 2026. The filing explicitly states "Falcon's Beyond Reports Second Quarter 2026 Financial Results" and includes consolidated revenue of $5.6 million, net loss of $0.3 million, and detailed financial statements (balance sheet, income statement, and cash flow statement). The press release is furnished as Exhibit 99.1 and is the core content of Item 2.02, which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-08-13
Item 2.03
Wabash National entered into a Sixth Amendment to its Second Amended and Restated Credit Agreement on August 12, 2026, amending its existing $300 million revolving credit facility with an option to increase by up to $175 million. The amendment modifies key terms including the maturity date (August 12, 2031) and financial covenants, constituting a material refinancing of the Company's primary credit facility.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a quarterly earnings release for Q2 2026 disclosing financial results including total revenue of $33.4 million, net product revenue of $30.8 million, and net loss of $67.0 million. The filing explicitly states the company "announced its financial results for the quarter ended June 30, 2026" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The release also includes forward guidance for full-year 2026 revenue and expense ranges.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-13
Item 5.02
Sprinklr appointed Jordi Ribas, Ph.D., a senior Microsoft executive with 26+ years of experience in Search & AI, to its Board of Directors as a Class II director effective August 17, 2026, following Board approval on August 10, 2026. Dr. Ribas was assigned to the Nominating and Corporate Governance Committee and Strategy Committee.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
MiNK Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly net loss ($3.1 million vs. $4.2 million prior year), cash position ($8.8 million), and per-share loss metrics ($0.62 vs. $1.06 prior year), along with clinical updates on the lead program agenT-797. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and clinical progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
The filing discloses Pyxis Oncology's financial results for the quarter ended June 30, 2026, including detailed condensed consolidated statements of operations and balance sheets. The press release (Exhibit 99.1) announces Q2 2026 financial results with specific metrics: net loss of $25.3 million ($0.40 per share), R&D expenses of $16.1 million, and cash position of $34.5 million as of June 30, 2026. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Accelerant Holdings issued a press release on August 13, 2026 disclosing Q2 2026 financial results ended June 30, 2026, including revenue of $356.9 million, net income of $80.0 million, and adjusted EBITDA of $93.1 million.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-13
Item 8.01
Accelerant Holdings executed an Agreement and Plan of Merger whereby Thoma Bravo affiliates will acquire the company in a change-of-control transaction, with Accelerant becoming a wholly owned subsidiary of the Sponsor. The company is canceling its earnings call and suspending guidance due to the pending transaction.
View raw filing on EDGAR →
6-K
Restatement
confidence 95%
filed 2026-08-13
EX-99.1
PLDT disclosed that it will amend its Form 20-F for fiscal year 2025 to correct financial statement errors related to hedge accounting and reclassifications, and to reflect a material weakness in internal controls over financial reporting. The independent auditor (SGV) has withdrawn its opinions on both internal controls and the financial statements. Although the company states the revisions are not expected to materially affect net income or key metrics, the withdrawal of audit opinions and the need to amend previously filed financial statements constitute a restatement under Item 4.02 standards.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-13
Item 5.07
Results of the Annual Meeting of Shareholders held on August 11, 2026, including election of eight directors to the Board, advisory vote on named executive officer compensation, and ratification of PricewaterhouseCoopers, LLP as independent auditor.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-13
Item 8.01
The Board of Directors declared a quarterly cash dividend of $0.28 per share, payable on September 8, 2026, to shareholders of record as of August 25, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Candel Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 13, 2026, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly R&D expenses ($19.8M vs. $7.0M YoY), G&A expenses ($6.9M vs. $4.2M YoY), net loss ($38.9M vs. $4.8M YoY), and cash position ($201.6M), along with operational highlights. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-13
Item 2.03
Sonida Senior Living entered into a $380.0 million senior secured term loan with Ally Bank on August 7, 2026, amending and restating its existing term loan agreement with a 5-year maturity and variable interest rate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Ondas Inc. issued a press release on August 13, 2026, announcing its financial and operating results for Q2 2026 ended June 30, 2026. The disclosure reports record revenue of $83.8 million (67% QoQ growth, 13-fold YoY growth), gross profit, backlog of $613 million reported ($757 million pro forma), and raised full-year 2026 revenue guidance to $525–$550 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($153.8M), revenue ($2.1M), operating expenses ($33.2M), and net loss ($30.2M per share), along with business updates on clinical programs (RECLAIM-LN, FT839, FT836) and corporate developments (Laura Hamill board appointment). The press release is attached as Exhibit 99.1 and covers both financial results and material operational milestones.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
The exhibit is a press release disclosing PLDT Inc.'s unaudited consolidated financial results for the six months ended June 30, 2026, including gross service revenues of ₱108.7 billion (up 2%), consolidated EBITDA of ₱56.1 billion (up 1%), and core income of ₱17.3 billion. This is a discrete earnings announcement, not a periodic financial report filing, and would materially affect a reasonable investor's assessment of the registrant's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
ARS Pharmaceuticals disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including Q2 2026 net product revenue of $26.2 million, total revenue of $33.7 million, operating expenses of $82.3 million, and net loss of $62.3 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's commercial progress with neffy and financial trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
CV Sciences disclosed its second quarter 2026 financial results on August 13, 2026, reporting revenue of $3.0 million (down 17.5% year-over-year), gross margin of 48.6%, operating loss of $0.3 million, and net loss of $0.775 million, along with consolidated financial statements and non-GAAP reconciliations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Kyntra Bio issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue, net income per share, and cash position. The filing discloses condensed consolidated balance sheets and statements of operations for the second quarter and six-month periods, which are typical components of an earnings release. This is a standard quarterly financial results disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-13
Item 2.01
Parker-Hannifin completed the acquisition of Filtration Group Corporation for $9.25 billion in cash on August 13, 2026, pursuant to a Merger Agreement entered into on November 10, 2025.
View raw filing on EDGAR →